Answers are grounded in this paper and cite their sources.
Choosing between targeted systemic biologics and oral small molecules for moderate-to-severe atopic dermatitis remains challenging, particularly with regard to early symptom control. This systematic review aimed to compare oral upadacitinib with subcutaneous dupilumab and placebo in phase III trials, focusing on early itch trajectories, skin clearance, and safety profiles. A comprehensive systematic search was conducted across PubMed/MEDLINE, Embase, the Cochrane Central Register of Controlled Trials (CENTRAL), Scopus, and Web of Science through October 2026. Prospective, double-blind, and open-label randomized controlled trials (RCTs) published between 2021 and 2026 and evaluating adult and adolescent populations receiving upadacitinib (15 mg or 30 mg) versus dupilumab or placebo were identified. Study quality and risk of bias were assessed using the Cochrane Risk of Bias 2 (RoB 2) tool. Four publications reporting five pivotal phase III trials, comprising 4,177 patients, were included in the qualitative synthesis. Upadacitinib demonstrated significantly greater early itch reduction, evident as early as week 1, and higher week 16 Eczema Area and Severity Index 75 (EASI-75) and Eczema Area and Severity Index 90 (EASI-90) response rates than the comparators. Upadacitinib was generally well tolerated. Treatment-emergent adverse events (TEAEs) primarily included mild-to-moderate, dose-dependent acne, upper respiratory tract infections, and transient laboratory abnormalities. No cases meeting Hy's law criteria were reported. Serious adverse events and treatment discontinuations were low and comparable across treatment groups. Clinical and methodological heterogeneity precluded quantitative pooling through meta-analysis. Although targeted systemic therapies demonstrate robust early efficacy, upadacitinib offers superior early itch reduction and higher short-term skin clearance rates than subcutaneous dupilumab. Oral upadacitinib represents a highly efficacious option for rapid symptom control; however, long-term pharmacovigilance and careful patient selection remain essential to minimize potential adverse events.
No takes yet. Share an insight, caveat, or question.
Prado et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: